Form 4: Tandem Diabetes Care CTO Rick Carpenter Awarded Significant Equity Incentives Under 2023 Plan

Tandem Diabetes Care's Chief Technology Officer, Rick Carpenter, was awarded 19,316 Performance Stock Units and 19,317 Restricted Stock Units on May 30, 2025, as part of the company's long-term incentive plan.

Summary

• Rick Carpenter, Chief Technology Officer of Tandem Diabetes Care Inc. (TNDM), was awarded equity incentives on May 30, 2025.
• The awards include 19,316 Performance Stock Units (PSUs) and 19,317 Restricted Stock Units (RSUs).
• These awards were granted pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan.
• PSUs are contingent rights to receive shares based on the achievement of pre-defined performance metrics by December 31, 2027, with potential payout ranging from 0% to 200% of the specified amount.
• RSUs represent a contingent right to receive shares or cash, with 33% vesting on May 15, 2026, and the remainder vesting in eight equal quarterly installments thereafter.
• Following these transactions, Rick Carpenter directly beneficially owns 21,020 shares of Tandem Diabetes Care Common Stock.

Sentiment

Score: 7

Explanation: The award of long-term equity incentives to a key executive like the CTO is generally positive as it aligns management's interests with long-term shareholder value and aids in executive retention. While not directly impacting immediate financial results, it signals stability in leadership and a commitment to future performance.

Positives

• The equity awards align the Chief Technology Officer's interests with the long-term performance and shareholder value of Tandem Diabetes Care.
• The awards serve as a retention mechanism for a key executive, promoting stability in leadership.
• The use of performance-based units (PSUs) ties a portion of compensation directly to the achievement of company-specific metrics, incentivizing strong operational results.
• The awards are made under an established and approved 2023 Long-Term Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The PSUs carry a risk of not vesting if the pre-defined performance metrics are not met by December 31, 2027, potentially resulting in no payout for that portion of the award.
• Both PSUs and RSUs are contingent on the awardee's continuing service through their respective vesting or measurement dates, meaning the executive must remain with the company to realize the full value.

Risks

• Performance Stock Units (PSUs) are subject to the achievement of pre-defined performance metrics as of December 31, 2027; if minimum performance is not met, no PSUs will vest.
• Both Performance Stock Units and Restricted Stock Units are subject to the awardee's continuing service through their respective vesting or measurement dates, posing a forfeiture risk if employment ceases.

Future Outlook

The equity awards, particularly the Performance Stock Units, indicate a forward-looking compensation strategy tied to the company's performance through December 31, 2027. The vesting schedule for Restricted Stock Units also extends into the future, suggesting a long-term commitment to executive retention and alignment with future company growth.

Management Comments

• The awards were made pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto.

Industry Context

The use of a combination of performance-based and time-based equity awards for executive compensation is a standard practice across the medical device and biotechnology industries. This approach aims to align executive incentives with long-term company performance and shareholder value, which is particularly crucial in innovation-driven sectors like diabetes care where sustained R&D and market penetration are key to success.

Comparison to Industry Standards

• The structure of equity compensation, combining Performance Stock Units (PSUs) and Restricted Stock Units (RSUs), is consistent with best practices observed in the medical technology sector, similar to compensation strategies at peers like Dexcom (DXCM) or Insulet (PODD).
• The performance period for PSUs extending to December 31, 2027, and the multi-year vesting schedule for RSUs are typical for long-term incentive plans designed to foster sustained executive focus on strategic objectives and financial growth.
• The potential payout range for PSUs (0% to 200%) is a common mechanism to provide strong upside potential for exceptional performance while mitigating risk for shareholders if targets are not met, aligning with competitive executive compensation frameworks.

Stakeholder Impact

• Shareholders: Potential for increased long-term value creation due to aligned executive incentives; potential for future dilution from the issuance of shares upon vesting of PSUs and RSUs.
• Employees: May signal stability in executive leadership and a commitment to long-term strategic goals, potentially fostering a positive work environment.

Next Steps

• Achievement of pre-defined performance metrics for Performance Stock Units by December 31, 2027.
• Vesting of Restricted Stock Units beginning May 15, 2026, with subsequent quarterly installments.

Key Dates

Recommendation

Keywords

Tandem Diabetes Care, TNDM, SEC Form 4, Insider Transaction, Equity Award, Performance Stock Units, Restricted Stock Units, Executive Compensation, Long-Term Incentive Plan, Rick Carpenter, Chief Technology Officer, Diabetes Technology